EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer

NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation test methods are performed. These studies should include the re-testing of stored non-small-cell lung cancer (NSCLC) tumour samples using different EGFR‑TK mutation test methods and should link to patient outcomes.

NICE recommends that a multivariate prediction model is developed with the aim of predicting the response of previously untreated, advanced or metastatic non-small-cell lung cancer NSCLC to treatment with an EGFR‑TK inhibitor.